AffinityImmuno Reveals Strong Preclinical Results

Charlottetown-based life sciences company AffinityImmuno has met with good results in preclinical trials for an antiviral compound that shows promise against COVID-19, with infected mice seeing as much as an 81 percent reduction in the amount of virus in their lungs within four days.
The animal trials began in 2021 under a partnership with the Robarts Research Institute at Western University in